<DOC>
	<DOCNO>NCT00211757</DOCNO>
	<brief_summary>The study design assess efficacy treatment divalproex sodium ( DS ) vs. placebo childhood/adolescent autism fulfil DSM-IV Autism Diagnostic Interview ( ADI ) criterion . Currently , FDA-approved treatment disorder , although behavioral educational therapy variety medication may play role management autistic symptom .</brief_summary>
	<brief_title>Divalproex Sodium v . Placebo Childhood/Adolescent Autism</brief_title>
	<detailed_description>This study compare divalproex sodium placebo treatment autistic disorder . Twenty six child adolescent outpatient , age range 5-17 , randomized 12-week double-blind , placebo-controlled parallel treatment study . During 12 week , patient monitor treat psychiatrist assess independent evaluator ( IE ) . The IE perform study assessment remain blind medication regimen ( include possible tapering ) well side effect . Study assessment administer designated time point</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Meets DSMIV , ADI , ADOS criterion autistic disorder Age 517 . Outpatients Parent/legal guardian signing informed consent , assent document patient demonstrate capacity provide . Sexually active female childbearing potential must use acceptable method birth control ( oral contraceptive medication [ administration must supervise parent guardian ] , IUD , depot medication tubal ligation ) negative serum pregnancy test prior entry study . Subject score least `` 4 '' ( moderately ill ) Clinical Global ImpressionSeverity Scale Autistic Disorder ( CGIAD ) . Subject meet follow criterion prestudy diagnostic assessment baseline assessment : OASM 13 ABCIrritability Subscale 18 ( raw score ) . Subjects history seizure , seizurefree 6 month stable dose anticonvulsant medication divalproex sodium relate formulation ( e.g. , depakene ) . Nonmedicated subject history seizure seizurefree 6 month . Subjects abnormal EEG clinical seizure . State exclusion criterion enrollment study : Subjects pregnant nursing mother . Sexually active woman childbearing potential use adequate birth control measure ( detail inclusion criterion ) . Subjects overall adaptive behavior score age two year Vineland Adaptive Behavior Rating Scale . Subjects active unstable epilepsy . Subjects follow past present mental disorder : schizophrenia , schizoaffective disorder organic mental disorder . Subjects serious suicidal risk . Subjects clinically significant unstable medical illness would contraindicate participation study , include hematopoietic cardiovascular disease , pancreatitis , liver toxicity , polycystic ovary syndrome . Subjects report history encephalitis , phenylketonuria , tuberous sclerosis , fragile X syndrome , anoxia birth , pica , neurofibromatosis , hypomelanosis Ito , hypothyroidism , Duchenne muscular dystrophy , maternal rubella . Patients history follow : gastrointestinal , liver , kidney , know condition presently interfere presently absorption , distribution , metabolism , excretion drug ; cerebrovascular disease brain trauma ; clinically significant unstable endocrine disorder , hypo hyperthyroidism ; recent history presence form malignancy Treatment within previous 30 day drug know welldefined potential toxicity major organ Subjects clinically significant abnormality laboratory test physical exam . Subjects likely require ECT psychotropic medication study , unless otherwise permit . Subjects unable tolerate taper psychoactive medication necessary . Subjects history hypersensitivity severe side effect associate use divalproex sodium , ineffective prior therapeutic trial divalproex sodium ( serum level within range 50100 ug/ml 6 week ) . Subjects receive following intervention within prescribed period start treatment : investigational drug within previous 30 day ; depot neuroleptic medication ; psychotropic drug permit concurrent use study within previous seven day ; fluoxetine within previous five week . Subjects begin new alternative nonmedication treatment , diet , vitamin , psychosocial therapy , within previous three month . Subjects organic systemic disease patient require therapeutic intervention , otherwise specify , would confound evaluation safety study medication . Subjects reside remote geographical area regular access transportation clinical facility .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>autism</keyword>
	<keyword>aggression</keyword>
	<keyword>irritability</keyword>
	<keyword>divalproex sodium</keyword>
</DOC>